5-BROMO-2-CHLORO-N-METHYLPYRIMIDIN-4-AMINE, 95.0%, 5g

8-Bromo-2-(trifluoromethyl)quinoline, 95.0%, 100mg

1,3-Dioxo-1,3-dihydroisobenzofuran-5-carboxylic acid, 97.0%, 100g

Pipette microlitre monocanal mLINE® variable, 0,1 à 3 µl, 1 pièce

N-Butyl-6-chloro-4-(trifluoromethyl)pyridin-2-amine, 95.0%, 5g

1-methyl-1H-1,2,4-triazol-3-amine hydrochloride, 95.0%, 10g

n-heptane, min.95%, pour la synthèse, 10 l, avec bl.

4-(2-Methoxyethoxy)cyclohexanol, 95.0%, 100mg

2-Chloro-4-(2,2,2-trifluoroethoxy)aniline, 95%, 100mg

1-(4-Bromophenyl)-7,8-dimethoxy-4-methyl-4,5-dihydro-3H-benzo[d][1,2]diazepine, 97%, 1g

1-Bromocyclopropanecarboxamide, 95.0%, 10g

methyl 4-(3,4-difluorophenyl)-6-(methoxymethylidene)-2-oxo-1,3-diazinane-5-carboxylate, 95%, 100mg

6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline, 95.0%, 5g